On 28 September, the construction of the Genesis facilities was officially launched by the Brussels-based global biopharmaceutical company UCB. UCB awarded BESIX the contract to build these new facilities in Braine l'Alleud, Belgium, last March and the building is expected to be operational in 2024.The 17,000 square meters facilities being built by BESIX are designed to accommodate particularly innovative services and comply with highest environmental standards. They will house cutting-edge laboratories and development facilities, production areas, and office spaces. One of its special features is also the flexibility of the building, with the possibility of easily reconfiguring the interior spaces.The new facilities are part of UCB's wider strategic development plan to provide Gene Therapy capabilities, including laboratories and production facilities, at its Braine l'Alleud site. This new biotechnology facility, one of the largest and most modern in Belgium, is being built to support the company's growth and prepare for the launch and long-term supply of future drugs currently in clinical development.